Beyond PSA: Managing modern therapeutic options in metastatic castration-resistant prostate cancer

Fatima H. Karzai, Ravi A. Madan, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. The role of the prostate-specific antigen in metastatic castrate-resistant prostate cancer has become more defined through the years. This article addresses how prostate-specific antigen criteria alone should not be used as a disease marker to discontinue therapy in metastatic castration-resistant disease.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalSouthern Medical Journal
Volume108
Issue number4
DOIs
StatePublished - 9 Apr 2015
Externally publishedYes

Keywords

  • PSAWG1
  • PSAWG2
  • androgen receptor
  • metastatic castration resistant
  • prostate-specific antigen

Fingerprint

Dive into the research topics of 'Beyond PSA: Managing modern therapeutic options in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this